Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting

• Eleven abstracts accepted for poster presentation highlight company’s differentiated antibody drug conjugate, multispecific antibody, and clinical product candidates
• Management will host a conference call on April 18^th at 6:30 pm Eastern Standard Time (EST)

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of eleven abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL from April 14 – 19, 2023.

“AACR represents an important opportunity for us to share recent progress in developing the next generation of novel therapeutics and highlights the unique capabilities of our proprietary engineering platforms and integrated technologies,” stated Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “The acceptance of eleven abstracts reflects the rapid progress we have made in developing our robust and differentiated pipeline. During the meeting we look forward to sharing new preclinical data on our anticipated 2024 IND candidates, ZW171 and ZW191, as well as other programs that represent potential future therapeutic opportunities and areas of interest.”

Presentation Details

Antibody Drug Conjugates

Title: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery

Abstract: 1538

Session Category: Experimental and Molecular Therapeutics

Session Title: Antibody Drug Conjugates

Title: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload

Abstract: 2641

Session Category: Experimental and Molecular Therapeutics

Session Title: Antibody Technologies

Title: ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload

Abstract: 1533

Session Category: Experimental and Molecular Therapeutics

Session Title: Antibody Drug Conjugates

Title: ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload

Abstract: 2658

Session Category: Experimental and Molecular Therapeutics

Session Title: Antibody Technologies

Multispecific Antibody Therapeutics

Title: ZW171, a T cell-engaging, bispecific antibody for the treatment of mesothelin-expressing solid tumors

Abstract: 2942

Session Category: Immunology

Session Title: Therapeutic Antibodies 2

Title: TriTCE Co-stim, next generation costimulatory trispecific T cell engagers for the treatment of solid tumors

Abstract: 5121

Session Category: Immunology

Session Title: Combination Immunotherapies 2

Title: TriTCE CPI, next generation trispecific T cell engagers with integrated checkpoint inhibition (CPI) for the treatment of solid tumors

Abstract: 2982

Session Category: Immunology

Session Title: Therapeutic Antibodies 3

Title: PROTECT™, a novel trispecific antibody masking platform with integrated immune modulation displays unique activity and differentiated modes of action

Abstract: 2926

Session Category: Immunology

Session Title: Therapeutic Antibodies 2

Title: ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity

Abstract: 2935

Session Category: Immunology

Session Title: Therapeutic Antibodies 2

Clinical Product Candidates

Title: ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1, study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers

Abstract: CT278¹

Session Category: Clinical Trials Posters

Session Title: Phase I Clinical Trials 2

Title: Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer

Abstract: 2633

Session Category: Experimental and Molecular Therapeutics

Session Title: Antibody Technologies

Abstracts can be found on AACR’s website located at www.aacr.org. Posters will be available at the time of presentation at the conference on the Company's website located at www.zymeworks.com.

Conference Call and Webcast Information:

Zymeworks management will host a conference call and webcast for investors and analysts on April 18, 2023, at 6:30 pm EST. The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ preclinical pipeline; the potential therapeutic effects of zanidatamab and Zymeworks’ other product candidates; Zymeworks’ clinical development of its product candidates and enrollment in its clinical trials; anticipated preclinical and clinical data presentations; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “anticipate”, “potential”, “will”, “continues”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct.

Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of the COVID-19 pandemic on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf, may be more severe and more prolonged than currently anticipated; the impact of new or changing laws and regulations; market conditions; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for its year ended December 31, 2022 (a copy of which may be obtained at www.sec.gov and www.sedar.com).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005744/en/